GU Cancers 2021 | Highlights in kidney and bladder cancer at ASCO GU 2021
Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, shares his highlights from ASCO GU 2021. Dr Grivas discusses updates from the EV-301 trial (NCT03474107), which is evaluating enfortumab vedotin versus chemotherapy, and the Phase III TROPiCS-04 trial (NCT04527991) investigating sacituzumab govetican for patients with locally advanced or metastatic urothelial cancer. Dr Grivas also outlines updates from the Phase II EV-201 trial (NCT03219333) investigating enfortumab vedotin for locally advanced or metastatic urothelial cancer and the Phase III CheckMate 274 trial (NCT02632409) investigating nivolumab following radical surgery for high-risk muscle-invasive urothelial carcinoma. Finally, Dr Grivas highlights results from two ongoing clinical trials in kidney cancer; the CLEAR study (NCT02811861) investigating lenvatinib plus pembrolizumab or lenvatinib plus everolimus versus sunitinib alone for patients with clear cell renal cell carcinoma, and the PAPMET (S1500) trial (NCT02761057) investigating cabozantinib, crizotinib, savolitinib and sunitinib. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Petros Grivas, MD, PhD, has received institutional research funding from Bavarian Nordic, Bristol-Myers Squibb, Clovis Oncology, Debiopharm, Immunomedics, Pfizer, Merck, QED Therapeutics, GlaxoSmithKline, Mirati Therapeutics and Kure It Cancer Research; and has participated in consultancy work with AstraZeneca, Dyania Health, EMD Serono, Immunomedics, Infinity Pharmaceuticals, Janssen, Merck, Mirati Therapeutics, Genentech, Pfizer and Seattle Genetics.
